# Tesamorelin FAQ: Questions from the Research Literature > Tesamorelin frequently asked questions: mechanism, dosage, safety, half-life, regulatory status, and comparative pharmacology. Answered from the peer-reviewed trial record. ## Frequently Asked Questions **What is tesamorelin?** Tesamorelin is a synthetic 44-amino-acid analogue of human GHRH(1-44)-NH2, modified at the N-terminus with a trans-3-hexenoic acid group. The FDA approved tesamorelin in 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. [1][9] **What does taking tesamorelin do?** Tesamorelin binds GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion. GH elevates hepatic IGF-1 via JAK2/STAT5 signaling. IGF-1 activates hormone-sensitive lipase in visceral adipocytes, producing selective reduction of visceral adipose tissue (VAT). [1][10] **Is tesamorelin FDA approved?** Yes. FDA approved tesamorelin under NDA 022505 in November 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Egrifta SV (2 mg/vial) was approved in 2019. No other indication has received regulatory approval. [1] **Does tesamorelin burn belly fat?** Phase III RCTs found statistically significant reductions in visceral adipose tissue: 15.2% reduction versus 5.0% increase in placebo at 26 weeks (Falutz 2007 [1]) and 18% sustained reduction at 52 weeks (Falutz 2008 [2]). The effect is specific to visceral fat; subcutaneous fat and BMI did not change significantly. **How long does tesamorelin take to reduce belly fat?** Meaningful VAT reduction begins around week 8 of daily administration, reaching peak effect by week 26. Effects are maintained and increase modestly through 12 months of continued administration. [2][3] Effect largely reverses within 12 weeks after discontinuation. [2] **What happens after you stop taking tesamorelin?** VAT reductions largely reversed within approximately 12 weeks of cessation in the Falutz 2008 and Falutz 2010 trials. [2][3] The visceral fat benefit is dependent on continued administration. **What are the risks of taking tesamorelin?** Most common adverse events: injection-site reactions, arthralgias, myalgias, and fluid retention. [1][2] Absolute contraindications: active malignancy, structural pituitary pathology, pregnancy, and hypersensitivity. IGF-1 and glucose monitoring are recommended throughout treatment. **Who should not take tesamorelin?** Active malignancy, pituitary tumor or structural pituitary damage, pregnancy, and hypersensitivity to GHRH analogues. [1][2] Caution in patients with pre-existing IGF-1 elevation or glucose dysregulation. **What are the long-term side effects of tesamorelin?** The 52-week and 12-month extension trials found the adverse event profile consistent with 26-week data — no new safety signals emerged. [2][3] The 2024 Fourman INSTI trial confirmed 12-month tolerability without glycemic worsening. [17] **What not to take with tesamorelin?** Corticosteroids may blunt the GH secretory response and reduce efficacy. [1] Co-administration with insulin or anti-diabetic agents may require dose adjustment. [11] **Does tesamorelin cause cancer?** No direct carcinogenicity was demonstrated in completed clinical trials. [1][2] Active malignancy is an absolute contraindication. Post-marketing surveillance has not documented a disproportionate cancer signal. **Is tesamorelin safe?** Phase III trial data and post-marketing experience describe a manageable safety profile. The NIH LiverTox database assigned tesamorelin a Score E (unlikely cause of liver injury). [19] A 12-week type 2 diabetes trial found no significant glucose or HbA1c changes. [11] **Is tesamorelin a steroid?** No. Tesamorelin is a peptide hormone analogue (GHRH analogue), not a steroidal compound. [9] It stimulates endogenous pulsatile GH secretion through the GHRH receptor pathway. **Is tesamorelin a peptide?** Yes. Tesamorelin is a 44-amino-acid synthetic peptide analogue of human GHRH(1-44)-NH2. Molecular weight is 5,135.8 Da. [9] **What is tesamorelin used for?** FDA-approved indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Research has also examined hepatic steatosis [5][6], cognitive function in older adults [7], body composition in type 2 diabetes [11], and efficacy in INSTI-treated HIV patients [17]. **How long does tesamorelin stay in your system?** Plasma half-life is approximately 26–38 minutes. [9] Downstream IGF-1 elevation persists for 12–24 hours after a single dose. **Does tesamorelin increase testosterone?** Published tesamorelin trials did not report significant testosterone elevation as a primary outcome. [1][2][3] The mechanism operates through the GH/IGF-1 axis, not gonadal steroidogenesis. **Does tesamorelin build muscle?** Some trials reported modest lean body mass increases; the 2026 meta-analysis quantified this at +1.42 kg. [16] Significant muscle hypertrophy was not a primary finding. **Is tesamorelin hard on your liver?** No hepatotoxicity signal has been documented. LiverTox Score E. [19] Prospective trials demonstrated hepatic fat reduction as the liver-relevant outcome. [5][6] **How to reconstitute tesamorelin?** Reconstitute with the supplied sodium chloride diluent using gentle swirling — not shaking — to avoid peptide degradation. [1] The resulting solution should be clear and colorless. **How long does tesamorelin last after reconstitution?** Use within 24 hours when stored at 2–8°C after reconstitution. [1] **Is tesamorelin better than sermorelin?** No head-to-head RCT exists. [9] Tesamorelin has a longer plasma half-life, DPP-IV resistance, and extensive Phase III human evidence for VAT reduction. **Can you take tesamorelin and sermorelin together?** No published trial has studied concurrent administration. Both act on the same GHRH receptor (GHRH-R), making additive benefit mechanistically uncertain. [1] **Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?** A secondary analysis of the Stanley 2014 JAMA trial and the Stanley 2019 Lancet HIV dedicated NAFLD trial demonstrated significant liver fat reduction. [5][6] Researchers have noted this as a potential investigational avenue in non-HIV populations; no non-HIV NAFLD trial has been completed. **How long does it take for tesamorelin to work?** GH pulse elevation and IGF-1 increase are measurable within hours of a single dose. [10] Meaningful VAT reductions require 8–12 weeks of daily administration. Body-composition changes are a weeks-to-months phenomenon. [1][3] ## References [1] Falutz J, et al. N Engl J Med. 2007;357(23):2359-70. https://pubmed.ncbi.nlm.nih.gov/18057338/ [2] Falutz J, et al. AIDS. 2008;22(14):1719-28. https://pubmed.ncbi.nlm.nih.gov/18690162/ [3] Falutz J, et al. J Acquir Immune Defic Syndr. 2010;53(3):311-22. https://pubmed.ncbi.nlm.nih.gov/20101189/ [5] Stanley TL, et al. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038357/ [6] Stanley TL, et al. Lancet HIV. 2019;6(12):e821-e830. https://pubmed.ncbi.nlm.nih.gov/31611038/ [7] Baker LD, et al. Arch Neurol. 2012;69(11):1420-9. https://pubmed.ncbi.nlm.nih.gov/22869065/ [9] González-Sales M, et al. Clin Pharmacokinet. 2015;54(3):285-94. https://pubmed.ncbi.nlm.nih.gov/25358450/ [10] Stanley TL, et al. J Clin Endocrinol Metab. 2011;96(1):150-158. https://pubmed.ncbi.nlm.nih.gov/20943777/ [11] Clemmons DR, et al. PLoS One. 2017;12(6). https://pubmed.ncbi.nlm.nih.gov/28617838/ [16] Rousakis A, et al. Obes Res Clin Pract. 2026;20(1):2-12. https://pubmed.ncbi.nlm.nih.gov/41545261/ [17] Fourman LT, et al. AIDS. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11365754/ [19] National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox. 2020. https://www.ncbi.nlm.nih.gov/books/NBK548730/ --- A peer-reviewed field record of the tesamorelin literature — FDA approvals, Phase III trials, and pharmacokinetics indexed here, not prescribed here.